What the FDA labels say about taking them together
Fenofibrate and fenofibric acid
Fenofibrate's FDA label of April 29, 2024 names fenofibric acid in its contraindications section, and fenofibric acid's label names fenofibrate too. The fenofibrate label: “… disease. nursing mothers. patients with known hypersensitivity to fenofibrate or fenofibric acid.”
Check it at the source: the fenofibrate FDA label on DailyMed (effective April 29, 2024, A-S Medication Solutions); the fenofibric acid FDA label on DailyMed (effective August 2, 2025, Aurobindo Pharma Limited).
What does the fenofibrate label say about fenofibric acid?
Fenofibrate label, contraindicationsCONTRAINDICATIONS TRICOR is contraindicated in: patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology ( 12.3 ) ]. patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions ( 5.2 ) ]. patients with preexisting gallbladder disease [see Warnings and Precautions ( 5.5 ) ]. nursing mothers [see Use in Specific Populations ( 8.2 ) ]. patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions ( 5.9 ) ].
Antara label (Lupin Pharmaceuticals, Inc., October 1, 2025), contraindicationsCONTRAINDICATIONS Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis ( 4 ) Active liver disease, including those with unexplained persistent liver function abnormalities ( 4 ) Pre-existing gallbladder disease ( 4 ) Hypersensitivity to fenofibrate fenofibric acid, or any of the excipients in Antara ( 4 ) Antara is contraindicated in patients with:
Antara label (Lupin Pharmaceuticals, Inc., October 1, 2025), warnings and precautionsAntara is contraindicated in patients with a hypersensitivity to fenofibrate, fenofibric acid, or any of the ingredients in Antara.
Lipofen label (ANI Pharmaceuticals, Inc., May 12, 2026), contraindicationsHypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in LIPOFEN.
Source: FDA drug label (Antara, NDA021695), Lupin Pharmaceuticals, Inc., effective October 1, 2025 (SPL set 24790a18-0291-4b88-a724-acac43b616ce), via openFDA
Source: FDA drug label (Lipofen, NDA021612), ANI Pharmaceuticals, Inc., effective May 12, 2026 (SPL set 78b789b9-854f-46b9-97f3-a48759a6ff89), via openFDA
Source: FDA drug label (Tricor), NDA021656 (Abbvie), as published by A-S Medication Solutions, effective April 29, 2024 (SPL set 84b2af1b-365e-4723-ac5f-bc826ec47772), via openFDA; the full label on DailyMed
What does the fenofibric acid label say about fenofibrate?
Fenofibric acid label, contraindicationsHypersensitivity to fenofibric acid, fenofibrate, or any of the excipients in fenofibric acid delayed-release capsules.
Fenofibric acid label, warnings and precautionsCholelithiasis: Fenofibrate may increase cholesterol excretion into the bile, leading to cholelithiasis.
Source: FDA drug label (FENOFIBRIC ACID), Aurobindo Pharma Limited, effective August 2, 2025 (SPL set 9ad201de-fa62-4c49-bc61-ee09b9ba434c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fenofibrate | Fenofibric acid | |
|---|---|---|
| Labeled for | High cholesterol, High triglycerides | High cholesterol, High triglycerides |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.103 per tablet 160 mg tablet | $0.286 per capsule 135 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once